Medicare Part D and Oncology

Video

Marc O'Connor, COO and chief strategy officer at Curant Health, discusses how the shift to Medicare Part D could impact patients undergoing treatment for cancer.

Marc O'Connor, COO and chief strategy officer at Curant Health, discusses how the shift to Medicare Part D could impact patients undergoing treatment for cancer.

Related Videos
Young depressed woman talking to lady psychologist during session, mental health - Image credit: motortion | stock.adobe.com
man taking opioid pills sitting at a dark table - Image credit: rohane | stock.adobe.com
schizophrenic man - mental disorder - Image credit: Andreza | stock.adobe.com
Related Content
Peach ribbon for endometrial cancer awareness -- Image credit: Chinnapong | stock.adobe.com

FDA Accepts sBLA for Dostarlimab With Chemotherapy to Treat Endometrial Cancer

April 25th 2024
Article
Pharmacy Focus: Policy Edition - Discussing the DRUG Act and PBM Reform

Pharmacy Focus: Policy Edition - Discussing the DRUG Act and PBM Reform

April 5th 2024
Podcast
Stem cell transplant procedure -- Image credit: Vadim | stock.adobe.com

Advancement in Stem Cell Transplantation: Improving Outcomes for Patients With Blood Cancer

April 25th 2024
Article
Pharmacy Focus: OTC Contraception and Reproductive Health

Pharmacy Focus: OTC Contraception and Reproductive Health

March 29th 2024
Podcast
Artificial intelligence -- Image credit: Shuo | stock.adobe.com

Optimizing Oncological Care: The Influence of AI on Insurance Approvals

April 24th 2024
Article
FDA approval stamp -- Image credit: Olivier Le Moal | stock.adobe.com

FDA Approves Lutathera for Pediatric Patients With SSTR+ Gastroenteropancreatic Neuroendocrine Tumors

April 23rd 2024
Article
© 2024 MJH Life Sciences

All rights reserved.